All articles by Allie Nawrat

1. Pfizer’s JAK1 inhibitor performs well in atopic dermatitis

   Pfizer has announced promising results from its Phase III JADE MONO-1 study of janus kinase 1 (JAK1) inhibitor abrocitinib in…
   Read More…

   14 Oct
2. From injections to pills: FDA approves first oral GLP-1 for type 2 diabetes

   Glucagon-like peptide 1 (GLP-1) is an incretin hormone, which stimulates insulin secretion. It is often found in low levels in…
   Read More…

   14 Oct
3. UCB acquires Ra Pharma for $2.1bn to enrich its rare disease portfolio

   UCB has acquired Massachusetts-based Ra Pharmaceuticals for $48 per share, bringing the total transaction to a value of approximately $2.1bn….
   Read More…

   11 Oct
4. ICER finds lack of evidence to support blockbuster drug price hikes

   A report by the Institute of Clinical and Economic Review (ICER) has determined that seven of the nine top-selling drugs…
   Read More…

   9 Oct
5. Pfizer licenses Akcea’s ANTPTL3-targetting drug for $250m

   Pfizer and Ionis subsidiary Akcea have signed a global exclusive licensing agreement for antisense therapy AKCEA-ANGPTL3-LRx. According to the terms…
   Read More…

   8 Oct
6. UK Government invests £35m into researching adolescent mental health

   The UK Government has launched a research project into understanding the causes of mental health problems in teenagers and young…
   Read More…

   7 Oct
7. ViiV unveils emotional challenges related to HIV ART treatment

   GSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency…
   Read More…

   4 Oct
8. Are we nearing the end of animal testing in pharma?

   Although animal testing for cosmetics is illegal across the European Union, as well as in many other countries, experimentation on…
   Read More…

   3 Oct
9. Keytruda approved in China as a monotherapy for NSCLC

   Merck has announced that Keytruda has been approved by the Chinese National Medical Products Administration (NMPA) as a monotherapy for…
   Read More…

   3 Oct
10. J&J resolves opioid lawsuits in two Ohio counties for $20.4m

    US pharma giant Johnson & Johnson (J&J) has announced the resolution and settlement of all opioid-based lawsuits with two Ohio…
    Read More…

    2 Oct